Implementation status of pharmacological studies in the development of orphan drugs

Author:

Yokoshiki Saki1,Arato Teruyo2ORCID

Affiliation:

1. Hokkaido University Graduate School of Medicine: Hokkaido Daigaku Daigakuin Igaku Kenkyuin

2. Hokkaido University Hospital: Hokkaido Daigaku Byoin

Abstract

Abstract Background: The nonclinical as well as clinical development of orphan drugs is difficult, owing to unknown pathophysiology and the absence of model animals. Both, the U.S. Food and Drug Administration (FDA) Guidance and European Medicines Agency (EMA) Guidelines, for orphan drug development describe non-clinical studies, but lack specific information, such as animal species and study design. Against this background, this study aimed to elucidate efficient methods for evaluating nonclinical efficacy based on a review report of orphan drugs approved in Japan. Results: A total of 184 orphan drugs, including 84 anticancer and 100 non-anticancer drugs, approved in Japan from January 2010 to December 2019 were investigated. Some anticancer drugs progressed to clinical development without distinct efficacy data in nonclinical studies. Patient-derived cells have been used for some drugs due to a lack of established cell lines. Cells used for non-clinical studies were devised for drugs indicated for cancers resistant to prior therapies, tumours with specific amino acid mutations in the target molecules, and solid tumours with specific biomarkers. For some non-anticancer drugs, similar disease model animals and normal animals were used for evaluation, since model animals did not exist. Biomarkers have been used specifically for evaluation in normal animals and as endpoints in some clinical trials. Conclusions: It was possible to evaluate drug efficacy by flexibly designing nonclinical studies according to disease characteristics for potentials orphan drugs. These approaches, which are not described in detail in the EMA Guideline or FDA Guidance, may thus allow lead approval.

Publisher

Research Square Platform LLC

Reference52 articles.

1. A human-on-a-chip approach to tackling rare diseases;Mello CPP;Drug Discov Today,2019

2. Big pharma moves from 'blockbusters' to 'niche busters';Dolgin E;Nat Med,2010

3. Passi I, Sushant, Kumar B, US-FDA Approved. Drugs in 2020 and 2021: A Review [published online ahead of print, 2022 Dec 8]. Mini Rev Med Chem. 2022;10.2174/1389557523666221208104530.

4. Drug discovery and development for rare genetic disorders;Sun W;Am J Med Genet A,2017

5. Guideline on Clinical Trials in Small Populations (London., 2006, Doc. Ref. CHMP/EWP/83561/2005). 2005; http://www.ema.europa.eu/docs/en_GB/ document_library/Scientific_guideline/2009/09/WC500003615.pdf. Accessed 15 Jun 2023.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3